• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email
    For Immediate Release:
    December 13, 2024

    Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

    “Today’s approval provides an important advance for patients with classic congenital adrenal hyperplasia and highlights the FDA’s continued commitment to advancing effective and safe treatments for rare diseases,” said Theresa Kehoe M.D., director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research. “The FDA will continue working with patients, drug companies and health care providers to address the unmet medical needs of the rare disease community.”

    Classic congenital adrenal hyperplasia is a rare genetic condition affecting the adrenal glands, which produce hormones such as cortisol and androgens. Patients with classic CAH do not produce enough cortisol and produce too many androgens. These patients require high doses of glucocorticoids (more than is typically needed to replace the deficient cortisol) because the glucocorticoids also help to reduce the excess levels of androgens. Crenessity works by reducing excessive adrenal androgen production, which helps reduce the amount of glucocorticoid treatment needed.

    Crenessity’s approval is based on two randomized, double-blind, placebo-controlled trials in 182 adults and 103 children with classic CAH. In the first trial, 122 adults received Crenessity twice daily and 60 received placebo twice daily for 24 weeks. After the first four weeks of the trial, the glucocorticoid dose was reduced to replacement levels, then adjusted based on levels of androstenedione, an androgen hormone. The primary measure of efficacy was the change from baseline in the total glucocorticoid daily dose while maintaining androstenedione control at the end of the trial. The group that received Crenessity reduced their daily glucocorticoid dose by 27% while maintaining control of androstenedione levels, compared to a 10% daily glucocorticoid dose reduction in the group that received placebo.  

    In the second trial, 69 pediatric patients received Crenessity twice daily and 34 received placebo twice daily for 28 weeks. The primary measure of efficacy was the change from baseline in serum androstenedione at week 4. The group that received Crenessity experienced a statistically significant reduction from baseline in serum androstenedione, compared to an average increase from baseline in the placebo group. At the end of the trial, patients assigned to Crenessity were able to reduce their daily glucocorticoid dose by 18% while maintaining control of androstenedione levels compared to an almost 6% daily glucocorticoid dose increase in patients assigned to placebo.

    Crenessity has a warning for acute adrenal insufficiency or adrenal crisis, which can occur if patients with underlying adrenal insufficiency who do not also receive adequate doses of glucocorticoid replacement therapy in situations associated with increased cortisol need (i.e., “stress dose steroids”). Crenessity should not be taken by patients with hypersensitivity to Crenessity’s active ingredient or any of its components.

    Because Crenessity is metabolized by a specific enzyme, using Crenessity at the same time as drugs that activate that enzyme can decrease the amount of Crenessity exposure and reduce Crenessity’s efficacy. Information about recommended dose adjustments is included in Crenessity’s full prescribing information. 

    The most common side effects of Crenessity in adults include fatigue, dizziness and arthralgia (joint pain). For pediatric patients, the most common side effects are headache, abdominal pain and fatigue.

    The FDA granted Crenessity Fast Track, Breakthrough Therapy, Orphan Drug and Priority Review designations.

    The FDA granted the approval of Crenessity to Neurocrine Biosciences, Inc.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    301-796-4540
    Consumer:
    888-INFO-FDA

    Get the next $NBIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$127.00Neutral
    Citigroup
    12/12/2023$136.00Buy
    Deutsche Bank
    More analyst ratings

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

      SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (CAH). "As a leader in CAH, Neurocrine is dedicated to expanding treatment

      6/30/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

      Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placeboFindings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) CongressSAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily INGREZZA® (valbenazine) capsules. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor dis

      6/27/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

      Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American Association of Nurse Practitioners (AANP) National Conference SAN DIEGO, June 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules. Findings will be prese

      6/20/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care